View Clinical Trial (Medical Research Study)

A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Mallignancies - NCT00569179-46202(Clinical Trial 193931)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Indianapolis
State:  
IN
Zip Code: 46202
Conditions: Leukemia, Myeloid, Acute - Leukemia, Lymphoid - Myelodysplastic Syndromes - Leukemia, Myelogenous, Chronic
Purpose: The purpose of this study is to determine the maximum tolerated dose of alloreactive NK cells that can be transfused following stem cell transplant.
Study summary:
Criteria: Inclusion Criteria: - Patients must have histologically documented AML, ALL, MDS, CML, - Identification of haploidentical donor - LVEF > 45% corrected - DLCO > 50% predicted - Serum Creatinine <= 2 mg/dL - Bilirubin < 2 x ULN - AST, ALT < 2 x ULN - Age ≤ 65 years - Performance Status 0-1 Exclusion Criteria: - Patients relapsing <6 months after autologous SCT are not eligible. - Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection - No HIV disease - Non-pregnant and non-nursing
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: July 12, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.